Trade Report: The Alnylam Pharmaceuticals Inc. (ALNY) Receives Outperform Rating from Cowen and Company

The Alnylam Pharmaceuticals Inc. (ALNY) Receives Outperform Rating from Cowen and Company

Cowen and Company reiterated their outperform rating on shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a report released on Saturday. They currently have a $100.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $150.00.

A number of other research analysts have also recently commented on ALNY. Credit Suisse Group AG reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Leerink Swann reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Zacks Investment Research cut Alnylam Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, June 27th. FBR & Co reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Friday, June 10th. Finally, Chardan Capital reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Monday, July 11th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $80.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.27 on Friday. Alnylam Pharmaceuticals has a 52 week low of $33.16 and a 52 week high of $110.75. The stock has a 50 day moving average price of $70.69 and a 200-day moving average price of $66.05. The firm’s market capitalization is $2.94 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. The business had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm’s revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. Analysts anticipate that Alnylam Pharmaceuticals will post ($4.68) EPS for the current fiscal year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares in the company, valued at $9,604,200.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 7.1% in the first quarter. Geode Capital Management LLC now owns 480,181 shares of the biopharmaceutical company’s stock valued at $30,123,000 after buying an additional 31,627 shares during the period. Altrinsic Global Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $4,250,000. AXA raised its stake in shares of Alnylam Pharmaceuticals by 50.5% in the first quarter. AXA now owns 98,689 shares of the biopharmaceutical company’s stock valued at $6,195,000 after buying an additional 33,116 shares during the period. State Street Corp raised its stake in shares of Alnylam Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 1,936,520 shares of the biopharmaceutical company’s stock valued at $121,553,000 after buying an additional 262,783 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Alnylam Pharmaceuticals by 348.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,321 shares of the biopharmaceutical company’s stock valued at $836,000 after buying an additional 10,348 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Related posts

Leave a Comment